Meeting
2022 ASCO Annual Meeting
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
Authors
Eugene R Ahn
Cancer Treatment Centers of America Chicago, Zion, IL
Eugene R Ahn , Herbert Leon Duvivier , Drew W. Rasco , Agnes Rethy , Chris Moore , Amy Yuet , Sandra R. Hankins , Rachael Orlandella , Swati Khanna , Joseph Dekker , Angela Georgy , David R. Spigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
NCT04795713
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2521)
DOI
10.1200/JCO.2022.40.16_suppl.2521
Abstract #
2521
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.
First Author: Minal A. Barve
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2022 ASCO Annual Meeting
Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors.
First Author: Gonzalo Tapia
Poster
2022 ASCO Annual Meeting
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).
First Author: Diwakar Davar